Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Salestools Logo

Salestools

L'agent IA #1 pour les équipes de vente et Go-to-Market. Vendez plus, plus vite, avec moins d'effort.

Produit

  • Agents de vente IA
  • Données d'intention
  • Données technologiques
  • Suivi des visiteurs
  • Copilote
  • Vente sociale

Solutions

  • Service client
  • E-commerce
  • SaaS
  • Entreprise
  • Petite entreprise

Ressources

  • Le rapport
  • Documentation
  • Référence API
  • Centre d'aide
  • Blog
  • Études de cas
  • Webinaires

Entreprise

  • À propos
  • Carrières
  • Presse
  • Contact
  • Partenaires

Nos bureaux

  • New York, HQ
  • Bucarest, Laboratoire de recherche IA
  • Zug, Suisse

© 2026 Salestools. Tous droits réservés.

Conditions relatives aux données et sécuritéPolitique de confidentialitéConditions de serviceAcceptable Use
Tous les systèmes opérationnels
Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Back to Reports
Fundraising

Jocasta Neuroscience

Jocasta Neuroscience Raises $35M in Series A

San Francisco, CAOctober 1, 20252 min read
Employees
50+

Jocasta Neuroscience Raises $35M in Series A


Jocasta Neuroscience has successfully raised $35M in a Series A at a $150M valuation led by Andreessen Horowitz bio, Khosla Ventures.


Company Overview


Jocasta Neuroscience is a Biotech company headquartered in San Francisco, CA, founded in 2023 with 50+ employees.


Developing longevity protein for neurodegenerative conditions


Fundraising Details


  • Amount Raised: $35M
  • Round Type: Series A
  • Valuation: $150M
  • Date: 2025-10-01
  • Investors: Andreessen Horowitz bio, Khosla Ventures

About Jocasta Neuroscience


Developing longevity protein for neurodegenerative conditions The company is positioned in the Biotech sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: San Francisco, CA
  • Founded: 2023
  • Team Size: 50+
  • Industry: Biotech

What This Means


This funding round demonstrates strong investor confidence in Jocasta Neuroscience's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. Jocasta Neuroscience's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $150M valuation marks an important milestone for Jocasta Neuroscience, positioning the company among notable players in the Biotech industry.


Looking Ahead


With this new capital, Jocasta Neuroscience is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2025-10-01. For more information about Jocasta Neuroscience, visit their headquarters at San Francisco, CA.

Company Info

Headquarters
San Francisco, CA
Founded
2023
Team Size
50+

Topics

Fundraising(2912)BiotechSeries AJocasta Neuroscience

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min read•$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free